Pharmaceutical Industry

Piramal sells 20% in pharmaceutical business to Carlyle for $490 mn

Carlyle will pick up a 20 per cent stake for $490 million or around Rs 3,700 crore in the pharma subsidiary called Piramal Pharma Ltd

Auto, pharma cos to continue with Chinese imports till alternatives emerge

In 2018-19, India imported auto components worth $17.6 billion, of which 27 per cent -- $4.75 billion -- were from China

Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.

Gilead Sciences developing easy-to-administer version of remdesivir

Remdesivir is the only drug so far that has been shown to help patients with Covid-19, but Gilead and other companies are looking for ways to make it work better.

KKR likely to pick 20% stake in Piramal Enterprises for Rs 3,500 crore

Talks are still in advanced stage with KKR, say bankers

Drug regulator asks traders to stock 55 ICU drugs for Covid-19 treatment

These drugs are in addition to the requirement to hydroxychloroquine and Azithromycin for patients, healthcare workers and household contacts of positive cases

Govt moves to check over-the-counter selling of coronavirus drugs

Sensing serious health risks, the government has swung into action. Dispensing of these medicines would get stricter and states have started collecting information on available stock in the market

Govt allows doorstep delivery of drugs to help citizens under lockdown

The health ministry invoked section 26B of the Drugs and Cosmetics Act, 1940 to facilitate the doorstep delivery of drugs to consumers

Tamil Nadu to set up Pharmaceutical Ingredients Park with Rs 770 crore

State has reported 15 positive Coronavirus cases so far

Pharmaceutical industry expects coronavirus vaccine in 12-18 months

The global death toll has risen to over 9,000 with more than 217,000 confirmed infections, according to an AFP tally based on official sources.

Big Pharma's addiction to profit

Book review of PHARMA: Greed, Lies, and the Poisoning of America

Sun Pharma stock sheds 15% on price fixing concerns, slow portfolio ramp-up

The near-term worry for the company is the ongoing investigation by the US Department of Justice related to price fixing and cartelisation by generic companies

Laudable move by Pharmexcil

The Pharmexcil came up with clarifications for its members and representations to the government highlighting some difficulties

Govt plans single-window assistance mechanism for pharma investors by March

On the sidelines of an annual event of the Indian Drug Manufacturers' Association, a senior government official said plans had been readied in this regard

Novartis, Merck, Allergan raise US prices, 445 drugs to cost more in 2020

That is above the average of 404 drug price increases in the first three days of January over the past five years

Gene therapy to conquering hepatitis C: A decade of medical breakthroughs

Putting aside prices for a moment, it's been an exciting period for medical progress

Aurobindo Pharma arm to buy certain biz assets of Profectus BioSciences

Aurobindo Pharma on Thursday said its subsidiary Auro Vaccines LLC has entered into a pact to acquire certain business assets from Profectus BioSciences Inc USA for an upfront cash consideration of USD 11.29 million (around Rs 80 crore) with potential earn-outs on achieving certain milestones. Auro Vaccines LLC is a wholly-owned subsidiary of Aurobindo Pharma USA Inc, USA, which is a wholly-owned arm of the company, Aurobindo Pharma said in a filing to the BSE. The indicative time period for completion of acquisition of research and development assets of Profectus BioSciences Inc is first half of 2020, it added. The acqusition provides access to proprietary and innovative technology platforms for prophylactic use and therapeutic use along with global R&D center, Aurobindo Pharma said. The acquisition will lead to enhancement of research and development capabilities and expertise in developing newer vaccines from basic discovery research into FDA-approved product, it added. Shares

Pharma sector to post moderate 7-9% CAGR due to healthy demand

The aggregate domestic growth was 27.2 per cent in June quarter, compared with 4.6 per cent in FY18 and minus 8.8 per cent in June quarter last year

Government mulls injecting Rs 4.6 bn into pharma to reduce bulk drugs cost

Five sub-schemes have been announced under the pharma development programme with the objective to reduce the cost of production by 20-25 per cent in bulk drug parks.

Sunrise at sunset point

To win the battle of perception, the Indian pharma industry should focus on capital allocation choices and capability building